Changes in skeletal and cardiac muscle mass
Time frame · 12 months
Status
Recruiting
Phase
Not applicable
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.
Interventions
No intervention details reported.
Timeline
First posted
Dec 9, 2025
Study start
May 15, 2026
Primary completion
Dec 31, 2027
Study completion
Apr 30, 2028
Results posted
Not reported
Registry updated
Jul 17, 2026
Outcomes
Changes in skeletal and cardiac muscle mass
Time frame · 12 months
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Adults 18-80 years of age * Starting semaglutide for type 2 diabetes or weight loss * Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment) Exclusion Criteria: * Current use of semaglutide for more than 2 weeks * Major recent heart issues or other severe health conditions * Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia) * Dependence on a mobility aid (unable to participate in exercise MRI)
Study locations
Canada. Showing up to 24 locations stored in the fast local snapshot.
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.